Page 17 - 202002
P. 17

[15] Zinman B, Aroda VR, Buse JB,               type  2  diabetes  [J].  The  New  England

         et  al.  Efficacy,  Safety,and  Tolerability  of     Journal  of  Medicine,2017;377(13):1228-
         Oral Semaglutide Versus Placebo Added                1239.
         to  Insufin  With  or  Without  Metformin  in             [21]  Marso  SP,  Daniels  GH,  Brown-

         Patients  With  Type  2  Diabetes:  The              Frandsen  K,  et  al.  Liraglutide  and
         PIONEER  8  Trial  [J].  Diabetes  Care,             cardiovascular  outcomes  in  type  2
         2019, 42(12): 2262-2271.
                                                              diabetes [J]. The New England Journal of

              [16]  Katagiri  H,  Hamamoto  Y,,               Medicine,2016;375(4):311-322.
         Deenadayalan  S,  et  al.  Dose-response,                 [22]  Hernandez  AF,  Green  JB,
         efficacy,  and  safety  of  oral  semaglutide        Janmohamed  S,  et  al.  Albiglutide  and

         monotherapy  in  Japanese  patients  with            cardiovascular  outcomes  in  patients  with
         type 2 diabetes (PIONEER 9): a 52-week,              type  2  diabetes  and  cardiovascular
         phase  2/3a,  randomised,  controlled  trial         disease (Harmony Outcomes): a double-

         [J].     The       Lancet       Diabetes        &    blind, randomised placebo-controlled trial
         Endocrinology,2020,8(5):377-391.
                                                              [J].  The  Lancet  2018;392(10157):1519-
              [17]  Katagiri  H,  Hamamoto  Y,                1529.

         Deenadayalan  S,  et  al.  Safety  and                    [23] Abbasi J. Oral GLP-1 Analog for
         efficacy  of  oral  semaglutide  versus              Type  2  Diabetes  on  the  Horizon  [J].
         dulaglutide in Japanese patients with type           JAMA, 2018, 320(6): 539.

         2 diabetes (PIONEER 10): an open-label,
         randomised,  active-controlled,  phase  3a             作者简介
         trial  [J].  The  Lancet  Diabetes  &                     傅润宸 山东第一医科大学药学院在读

         Endocrinology,2020,8(5):392-406.                     本科生,药学专业,健康与医学科普理论

              [18]  Husain  M,  Birkenfeld  AL,               研究课题组成员,课题研究主要方向为药
         Donsmark M, et al. Oral Semaglutide and              学科普与精准传播。曾参加过《中国医学

         Cardiovascular Outcomes in Patients with             伦理学》杂志和健康报社将联合举办的“万
         Type 2 Diabetes [J]. N Engl J Med,2019,              众一心战疫情,人文关怀在践行” 颁奖暨学
         381(9): 841-851.                                     术论坛中“弘扬伟大的抗疫精神 做新时代合
                                                              格接班人倡议书”联合署名活动。
              [19] Pfeffer MA, Claggett B, Diaz R,
         et al. Lixisenatide in patients with type 2               刘思彤 北京大学药学院硕士研究生,
         diabetes  and  acute  coronary  syndrome             中国医药卫生协会全民健康素养促进分会

         [J].  The  New  England  Journal  of                 青委会委员,研究方向是临床药学、合理
         Medicine,2015,373(23):2247-2257.                     用药、药学科普等。致力于提升公众用药
                                                              素养的工作与研究,新冠肺炎疫情期间积
              [20]  Holman  RR,  Bethel  MA,  Mentz           极参与相关调研,发表疫情相关论文2篇。

         RJ,  et  al.  Effects  of  once-weekly               E-mail:lst19970119@163.com
         exenatide on cardiovascular outcomes in






                                                          c̾̀ḤḤc
   12   13   14   15   16   17   18   19   20   21   22